Avantax Advisory Services Inc. Takes $145,000 Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Avantax Advisory Services Inc. acquired a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 10,973 shares of the company’s stock, valued at approximately $145,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC raised its position in Takeda Pharmaceutical by 10.9% during the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after buying an additional 286,052 shares during the period. Stifel Financial Corp lifted its position in shares of Takeda Pharmaceutical by 103.9% in the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after purchasing an additional 224,594 shares in the last quarter. Crossmark Global Holdings Inc. boosted its holdings in shares of Takeda Pharmaceutical by 284.9% during the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock worth $2,787,000 after purchasing an additional 155,795 shares during the period. Raymond James Financial Inc. purchased a new position in Takeda Pharmaceutical during the fourth quarter valued at approximately $1,447,000. Finally, Verition Fund Management LLC acquired a new position in Takeda Pharmaceutical in the 3rd quarter valued at approximately $1,533,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Up 0.8 %

TAK stock opened at $15.15 on Friday. The company has a 50 day moving average of $14.12 and a two-hundred day moving average of $13.93. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a 12-month low of $12.58 and a 12-month high of $15.31. The company has a market cap of $48.19 billion, a price-to-earnings ratio of 37.86, a PEG ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, equities analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.